1223498-63-2

Upstream product

• 1223498-62-1 (R,S)-S-ethyl-S-(4-nitrophenyl)-N-(trifluoroacetyl)sulfoximide 
• 7205-60-9 1-(ethylsulfanyl)-4-nitrobenzene 
• 851008-74-7 (R,S)-S-ethyl-S-(4-nitrophenyl)sulfoximide 
• 7205-70-1 (R,S)-1-(ethylsulfinyl)-4-nitrobenzene 
• 1849-36-1 para-nitrobenzenethiol 

Downstream Products

• 1223498-81-4 C₁₇H₂₂F₃N₅O₂S 
• 1223498-78-9 C₁₇H₂₂F₃N₅O₂S 
• 1223498-83-6 C₁₈H₂₄F₃N₅O₂S 
• 1223498-82-5 C₁₈H₂₄F₃N₅O₂S 
• 1223498-32-5 (RS)-S-ethyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]amino}-5-(trifluoromethyl)-pyrimidin-2-yl]amino}phenyl)sulfoximide 

Relevant academic research and scientific papers

The lab oddity prevails: Discovery of Pan-CDK inhibitor (R)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY1000394) for the treatment of cancer

Lead optimization of a high-throughput screening hit led to the rapid identification of aminopyrimidine ZK304709, a multitargeted CDK and VEGF-R inhibitor that displayed a promising preclinical profile. Nevertheless, ZK304709 failed in phaseI studies due

SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE

The invention relates to sulfoximine-substituted anilino-pyrimidine derivatives of formula (I). methods of production thereof, and use thereof as medication for the treatment of various diseases.